Gilead acquired YM BioSciences for ~$510M cash; brought momelotinib (CYT387) JAK inhibitor as Gilead's first oncology MPN program. Asset later divested to Sierra Oncology in 2018.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Terminated
Assessment window: 5yr post-close.
Key facts
AnnouncedDec 12, 2012
ClosedFeb 08, 2013
Deal value$510M
Deal typeAcquisition/Merger
Therapeutic areaMyelofibrosis
IndicationsMyelofibrosis
Key assetsMomelotinib (CYT387)
MechanismJAK1/JAK2 selective inhibitor (later also ACVR1)